We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in... Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. Show more
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in...
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation...
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 0.315457413249 | 3.17 | 3.6 | 3.105 | 876919 | 3.29613398 | CS |
4 | -1.54 | -32.6271186441 | 4.72 | 5.025 | 3.105 | 817920 | 3.72984283 | CS |
12 | -1.71 | -34.9693251534 | 4.89 | 6.52 | 3.105 | 623887 | 4.80948438 | CS |
26 | -0.9 | -22.0588235294 | 4.08 | 7.25 | 3.105 | 893343 | 5.01199179 | CS |
52 | -3.94 | -55.3370786517 | 7.12 | 8.885 | 3.105 | 983895 | 5.80338133 | CS |
156 | -19.82 | -86.1739130435 | 23 | 29.88 | 3.105 | 1033605 | 9.69869871 | CS |
260 | -19.82 | -86.1739130435 | 23 | 29.88 | 3.105 | 1033605 | 9.69869871 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions